The MAP TRIAL: PHASE III STUDY OF MUSCADINE PLUS (MPX) IN MEN WITH PROSTATE CANCER: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF MPX CAPSULES ON RISING PROSTATE-SPECIFIC ANTIGEN LEVELS IN ALANINE/ALANINE SOD2 GENOTYPE MEN FOLLOWING INITIAL THERAPY FOR PROSTATE CANCER

IRB/UVA Tracking #
21302
Contact
Julio Torres
Contact Email
Contact Phone
1.434.982.4110
Phase
III
Primary purpose
Treatment
Cancer PI
Robert Dreicer
Status
OPEN TO ACCRUAL
Ages
Adult